P2RX4 and myeloid sarcoma: Carriage of P2RX4 rs28360472:GG was associated with an increased risk of MS susceptibility (OR: 10.8, 95% CI: 2.7–43.7, P = 0.0009***, vs. A/A; see Table 4 and Fig. 2c).